• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

银屑病生物治疗与精神疾病无关:一项电子病历队列研究。

Lack of association of biologic therapy for psoriasis with psychiatric illness: An electronic medical records cohort study.

机构信息

Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.

Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.

出版信息

J Am Acad Dermatol. 2019 Sep;81(3):709-716. doi: 10.1016/j.jaad.2019.04.055. Epub 2019 May 2.

DOI:10.1016/j.jaad.2019.04.055
PMID:31054973
Abstract

BACKGROUND

Psoriasis and biologic therapies have been associated with psychiatric illnesses.

OBJECTIVE

To determine if persons with psoriasis or those exposed to biologics are more likely to develop a psychiatric illness.

METHODS

Retrospective electronic medical records cohort study.

RESULTS

Individuals with psoriasis were significantly more likely to have a history of several medical (eg, cardiovascular illnesses) and psychiatric (eg, depression, suicide) illnesses than those without psoriasis. Those with psoriasis who were prescribed a biologic therapy were significantly less likely than those with psoriasis not prescribed a biologic agent to receive a psychiatric illness diagnosis (hazard ratio for any psychiatric illness 0.52, 95% confidence interval 0.51-0.53, P < .0001). With respect to any psychiatric illness, this finding was confirmed when comparing biologic therapy versus methotrexate treatment (0.80, 95% confidence interval 0.76-0.84, P < .0001).

LIMITATIONS

These findings were likely attributable to treatment selection bias.

CONCLUSION

Individuals with psoriasis have an increased risk of several medical and psychiatric illnesses. Individuals with psoriasis prescribed biologic agents are less likely than those not prescribed biologic agents to develop psychiatric illnesses. Most likely because of treatment selection, individuals with psoriasis prescribed biologic therapy are not currently at increased risk of a psychiatric outcome.

摘要

背景

银屑病和生物疗法与精神疾病有关。

目的

确定患有银屑病或接触过生物制剂的人是否更有可能患上精神疾病。

方法

回顾性电子病历队列研究。

结果

与没有银屑病的人相比,患有银屑病的人更有可能患有多种医学疾病(如心血管疾病)和精神疾病(如抑郁、自杀)。与未接受生物制剂治疗的银屑病患者相比,接受生物治疗的银屑病患者被诊断出患有精神疾病的可能性显著降低(任何精神疾病的风险比为 0.52,95%置信区间为 0.51-0.53,P<0.0001)。对于任何精神疾病,与接受甲氨蝶呤治疗相比,这一发现得到了证实(0.80,95%置信区间为 0.76-0.84,P<0.0001)。

局限性

这些发现可能归因于治疗选择偏倚。

结论

患有银屑病的人患多种医学和精神疾病的风险增加。与未接受生物制剂治疗的患者相比,接受生物制剂治疗的银屑病患者发生精神疾病的可能性较低。最有可能是由于治疗选择,目前接受生物治疗的银屑病患者没有增加患精神疾病的风险。

相似文献

1
Lack of association of biologic therapy for psoriasis with psychiatric illness: An electronic medical records cohort study.银屑病生物治疗与精神疾病无关:一项电子病历队列研究。
J Am Acad Dermatol. 2019 Sep;81(3):709-716. doi: 10.1016/j.jaad.2019.04.055. Epub 2019 May 2.
2
Age and biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).中重度银屑病患者的年龄与生物学生存:来自英国皮肤科医师协会生物制剂和免疫调节剂登记处(BADBIR)的队列研究
Br J Dermatol. 2025 Apr 28;192(5):907-916. doi: 10.1093/bjd/ljaf017.
3
Prescribing Patterns Associated With Biologic Therapies for Psoriasis from a United States Medical Records Database.来自美国医疗记录数据库的银屑病生物疗法相关处方模式。
J Drugs Dermatol. 2019 Aug 1;18(8):745-750.
4
Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis.银屑病患者不同治疗方案中的不良医疗状况:基于索赔数据的分析
J Drugs Dermatol. 2018 Nov 1;17(11):1211-1218.
5
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).银屑病的生物制剂和系统治疗的严重感染风险:来自银屑病纵向评估和登记研究(PSOLAR)的结果。
JAMA Dermatol. 2015 Sep;151(9):961-9. doi: 10.1001/jamadermatol.2015.0718.
6
Patient Characteristics, Health Care Resource Utilization, and Costs Associated with Treatment-Regimen Failure with Biologics in the Treatment of Psoriasis.治疗银屑病的生物制剂治疗失败相关的患者特征、医疗资源利用和成本。
J Manag Care Spec Pharm. 2016 Apr;22(4):396-405. doi: 10.18553/jmcp.2016.22.4.396.
7
Serial biologic therapies in psoriasis patients: A 12-year, single-center, retrospective observational study.银屑病患者的序贯生物治疗:一项 12 年、单中心、回顾性观察研究。
J Am Acad Dermatol. 2020 Jan;82(1):37-44. doi: 10.1016/j.jaad.2019.05.064. Epub 2019 May 29.
8
Serious infections among a large cohort of subjects with systemically treated psoriasis.一大群接受全身治疗的银屑病患者中的严重感染
J Am Acad Dermatol. 2017 Nov;77(5):838-844. doi: 10.1016/j.jaad.2017.07.047. Epub 2017 Sep 13.
9
Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.生物疗法和传统全身疗法在中重度银屑病老年和成年患者中显示出相似的安全性和疗效。
J Drugs Dermatol. 2015 Aug;14(8):846-52.
10
Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.将生物疗法与银屑病的其他全身治疗相结合:来自国家银屑病基金会医学委员会的循证、最佳实践建议。
JAMA Dermatol. 2015 Apr;151(4):432-8. doi: 10.1001/jamadermatol.2014.3456.

引用本文的文献

1
Using Guidelines of Care to Lower Cardiovascular Risk in Patients with Psoriasis.使用临床实践指南降低银屑病患者心血管风险
Dermatol Clin. 2024 Jul;42(3):417-428. doi: 10.1016/j.det.2024.02.008. Epub 2024 Feb 26.
2
Risk for incident suicidality among psoriasis patients: a systematic review and meta-analysis.银屑病患者发生自杀行为的风险:一项系统评价和荟萃分析。
Arch Dermatol Res. 2023 Apr;315(3):455-465. doi: 10.1007/s00403-022-02377-5. Epub 2022 Aug 12.
3
Long-Term Infliximab Treatment in Psoriasis Patients: A National Multicentre Retrospective Study.
银屑病患者的长期英夫利昔单抗治疗:一项全国多中心回顾性研究。
Dermatol Res Pract. 2020 Mar 9;2020:2042636. doi: 10.1155/2020/2042636. eCollection 2020.